Retatrutide, explained plainly
What it is, why it acts on three receptors, how long it lasts in the body, and how far it has got with regulators.
5 min read · 2026-11-17
What it is, why it acts on three receptors, how long it lasts in the body, and how far it has got with regulators.
5 min read · 2026-11-17
Retatrutide is a single peptide built to switch on three receptors at once: the GIP receptor, the GLP-1 receptor and the glucagon receptor 16. It was first published under the developer code LY3437943 6.
In its trials it is given as an injection under the skin once a week 1. It is investigational: the phase 3 report published in 2026 describes it as under clinical development, and no source on its page records a marketing authorization 4.
One molecule, what it acts on
What it binds, and what each receptor is known to do. Pick one.
GIP receptor. In vitro the molecule is more active here than at the other two receptors. In obese mice the discovery paper credits GIP and GLP-1 receptor activity with the reduction in calorie intake 6.
The idea came in steps. A review of the mechanisms describes the sequence: the known actions of GLP-1 and of GIP alone, then single molecules that activate both of those receptors, and now molecules that also bind the glucagon receptor 8.
In obese mice, the discovery paper credits the fall in calorie intake to GIP and GLP-1 receptor activity, and reports that weight loss was increased by a rise in energy expenditure through the glucagon receptor 6. That is a finding in mice. An animal result is not a result in people.
What each receptor adds in people is less settled. A scoping review of dual and triple agonists reports that the extra benefit from the glucagon receptor was largely unexpected, and that whether the three signaling pathways help or hinder each other when stimulated together is not known 8.
In the phase 1b trial in adults with type 2 diabetes, the half-life was approximately 6 days 5. A half-life is the time it takes for the amount in the blood to fall by half. A half-life of about six days is what makes a once-weekly schedule possible in the trials.
Retatrutide has reached phase 3: large randomized trials. The first phase 3 results, from TRANSCEND-T2D-1 in type 2 diabetes, were published in 2026 4. Reaching phase 3 is not a license. A regulator has to review the whole program first, and none has recorded an authorization in the sources on its page.
How far it has climbed
Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.
A regulator has reviewed the trials and licensed it for a named use.
Large randomized trials, often thousands of people, against placebo or a standard treatment.
Mid-sized trials that measure dose against effect in people with the condition.
First studies in people: safety, and how the body handles it.
Laboratory and animal work. An animal result is not a result in people.
A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16
From first trial to today
Retatrutide: year by year. Scroll sideways for the whole ribbon.
The phase 1b trial in type 2 diabetes begins enrolling in December, at four centers in the USA 5.
The phase 2 obesity trial is registered and randomizes its first participants; the phase 2 diabetes trial begins 210.
The discovery paper and the phase 1b results are published under the code LY3437943 56.
The phase 2 results in obesity and in type 2 diabetes are published 12.
The MASLD substudy is published; TRANSCEND-T2D-1 begins randomizing; a head-to-head trial against tirzepatide is registered 3412.
A systematic review and meta-analysis pools four placebo-controlled trials 7.
The TRANSCEND-T2D-1 results and the TRANSCEND-CKD design paper are published 49.
The numbers are those of the Retatrutide page, where every source is listed.